LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Status:
Completed

Trial end date:
2017-07-06

Target enrollment:

Participant gender:

A study of LEO 32731 in the treatment of psoriasis vulgaris

Phase 2

LEO Pharma